Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California.
Technical indicators:
- 100.90+ Weighted Alpha
- Trend Spotter buy signal
- Above its 20, 50 and 100 day moving averages
- 9 new highs and up 48.30% in the last month
- Relative Strength Index 78.83%
- Barchart computes a technical support level at 23.69
- Recently traded at 26.90 with a 50 day moving average of 19.28
Fundamental factors:
- Market Cap $661.74 million
- New so not closely followed
- Has had 2 great earnings surprises
- Earnings estimated to increase 35.90% this year ad an additional 10.70% next year
- Wall Street analysts issued 2 strong buy and another buy recommendation
- Only 1 individual investor on Motley Fool follows the stock and they have an Outperform opinion
No comments:
Post a Comment